IP Library Granted Patent US 10,273,516
Granted Patent B2
US 10,273,516 · App. 14/708,568 · Granted Apr 30, 2019

Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,273,516
App. No.
14/708,568
Granted
Apr 30, 2019
Kind
B2
Abstract

The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.

Claims (12)

1. An isolated Escherichia coli ( E. coli ) bacterium comprising a genetic modification to reduce β-galactosidase activity, a defective colanic acid synthesis pathway, and an isolated nucleic acid encoding a lactose-accepting α (1,2) fucosyltransferase enzyme, wherein the sequence of said α (1,2) fucosyltransferase enzyme comprises a Bacteroides vulgatus ATCC 8482 glycosyl transferase family protein (FutN).

2. The isolated E. coli bacterium of claim 1 , wherein an endogenous lacZ gene and an endogenous lacI gene of said E. coli bacterium are deleted or functionally inactivated.

3. The isolated E. coli bacterium of claim 2 , wherein said E. coli bacterium comprises a lacIq gene promoter upstream of a lacY gene.

4. The isolated E. coli bacterium of claim 1 , wherein an endogenous wcaJ gene of said E. coli bacterium is deleted or functionally inactivated.

5. The isolated E. coli bacterium of claim 1 , wherein said bacterium further comprises a mutation in an adenosine-5′-triphosphate (ATP)-dependent intracellular protease.

6. The isolated E. coli bacterium of claim 1 , wherein said bacterium accumulates intracellular lactose in the presence of exogenous lactose.

7. The isolated E. coli bacterium of claim 1 , wherein said bacterium accumulates intracellular guanosine diphosphate (GDP)-fucose.

8. The isolated E. coli bacterium of claim 1 , wherein the amino acid sequence of said FutN comprises SEQ ID NO:8.

9. The isolated E. coli bacterium of claim 1 , wherein said E. coli bacterium comprises the genotype ΔampC::P trp B cI, Δ(lacI-lacZ)::FRT, P lacIq lacY + , ΔwcaJ::FRT, thyA::Tn10, Δlon:npt3, (lacZ + ).

10. The isolated E. coli bacterium of claim 5 , wherein said mutation in said ATP-dependent intracellular protease is a mutation in a lon gene.

11. The isolated E. coli bacterium of claim 1 , wherein said bacterium further comprises a mutation in a lacA gene.

12. The isolated E. coli bacterium of claim 1 , wherein said bacterium further comprises a mutation in the thyA gene.

Assignments (2)
SECURITY INTEREST Recorded May 12, 2022
From: GLYCOSYN LLC; GLYCOSYN, INC.
To: GINKGO BIOWORKS, INC.
Reel/Frame 060052/0477 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2015
From: HEIDTMAN, MATTHEW IAN; MERIGHI, MASSIMO; MCCOY, JOHN M.
To: GLYCOSYN LLC
Reel/Frame 036249/0808 →